Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-02-05

Clinical Trial Update: Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the effects of dapagliflozin 10 mg on insulin resistance in patients with type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2018-02-05